• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.00 EUR

-1.64 %

5,649 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-1.64 %
+2.62 %
-1.75 %
-36.62 %
-37.28 %
+7.66 %
+163.93 %
+91.90 %
-98.51 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
72.67M EUR
Turnover
13.54K EUR
P/E (adj.) (26e)
72.06
EV/EBIT (adj.) (26e)
58.34
P/B (26e)
7.11
EV/S (26e)
5.54
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
2026-05-14
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-05-15

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
NBS6 received marketing authorization for Australia. nexstim.com Nexstim - Releases
6/3/2026, 7:19 AM
by ghoul
44
Based on a quick calculation, the shareholdings of eight management team or board members in the top 100 have increased by thousands of shares in May. That, if anything, increases my own confidence in the company’s performance.
6/1/2026, 8:37 PM
22
Here are Antti’s comments on how Nexstim received marketing authorization for the NBS 6 system in Australia Inderes – 4 Jun 26 Nexstim sai uuden myyntiluvan NBS 6 -laitteistolle Australiassa - Inderes Myyntilupalaajentaa NBS 6 -laitteiston käytön diagnostiikkaan ja kuntoutukseen.
6/4/2026, 5:25 AM
by Sijoittaja-alokas
12
Yes, Nexstim has planned to use the money for something; the core business would hardly need such an arrangement. Bittium’s reports contain the following regarding their neuro-business: “EEG and EMG solutions will remain in the company’s portfolio, but as the markets for these products...
6/3/2026, 10:59 AM
by AccionHombre
11
nexstim.com Nexstim - Nexstimin suurimmat osakkeenomistajat Everything is looking very green (positive). Of course, most of the green is related to recent events. It’s great to see the insiders appearing more prominently on the lists.
6/1/2026, 8:49 AM
by Jatast
11
There must certainly be a weighty reason for this arrangement and why it was organized this way instead of a rights issue for existing shareholders. Could it be a sudden situation? If the circumstances had been explained more thoroughly and a standard share issue had been organized...
6/3/2026, 8:43 AM
by Jatast
9
If we’re going to split hairs here, the majority of those top 100 increasers were certainly not involved in the arrangement made in connection with Eiffel. It could, of course, be related in the sense that the investment and the arrangement have been perceived as a positive thing...
6/1/2026, 12:09 PM
by Kyhnykeisari
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment6/4/2026, 5:48 AM by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release6/3/2026, 7:00 AM

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release5/25/2026, 6:00 AM

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/18/2026, 2:00 PM

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release5/15/2026, 11:40 AM

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Nexstim strengthens its balance sheet
Research5/15/2026, 6:00 AM by
Antti Siltanen

Nexstim strengthens its balance sheet

The 5 MEUR financing supports the growth strategy.

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Regulatory press release5/13/2026, 2:00 PM

Nexstim Plc: Managers’ Transactions, Juokslahti

Nexstim
Regulatory press release5/13/2026, 12:00 PM

Nexstim Plc: Disclosure of change in holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release5/13/2026, 6:05 AM

Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option Holders

Nexstim
Press release5/5/2026, 6:00 AM

Nexstim Receives NBS 6 System Order from Children’s Hospital in the U.S.

Nexstim
Nexstim Q1'26: The year started with three system deliveries
Analyst Comment4/29/2026, 6:38 AM by
Antti Siltanen

Nexstim Q1'26: The year started with three system deliveries

The seasonally quiet start to the year proceeded as expected.

Nexstim
Press release4/28/2026, 6:00 AM

Nexstim Plc Business Update Q1 2026

Nexstim
Regulatory press release4/17/2026, 6:00 AM

Nexstim Plc establishes Restricted Share Unit plan for extended management team for earning periods 2026-2029

Nexstim